Dual Role For A MEK Inhibitor As A Modulator Of Inflammation And Host Defense Mechanisms With Potential Therapeutic Application In COPD

References

• Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med. 2009;360(23):2445–2454. doi:10.1056/NEJMra080475219494220
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Burney PGJ, Silverman EK, et al. Chronic obstructive pulmonary disease. Nat Rev Dis Primers. 2015;1:15076. doi:10.1038/nrdp.2015.7627189863
   PubMed Web of Science ®Google Scholar
• Wilkinson TMA, Aris E, Bourne S, et al. A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD. Thorax. 2017;72(10):919–927. doi:10.1136/thoraxjnl-2016-20902328432209
   PubMed Web of Science ®Google Scholar
• Gunawardana N, Finney L, Johnston SL, Mallia P. Experimental rhinovirus infection in COPD: implications for antiviral therapies. Antiviral Res. 2014;102:95–105. doi:10.1016/j.antiviral.2013.12.00624370732
   PubMed Web of Science ®Google Scholar
• Mallia P, Footitt J, Sotero R, et al. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(11):1117–1124. doi:10.1164/rccm.201205-0806OC23024024
   PubMed Web of Science ®Google Scholar
• Molyneaux PL, Mallia P, Cox MJ, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188(10):1224–1231. doi:10.1164/rccm.201302-0341OC23992479
   PubMed Web of Science ®Google Scholar
• Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Sys Rev. 2014;(3). doi:10.1002/14651858.CD010115.pub2
   Web of Science ®Google Scholar
• Renda T, Baraldo S, Pelaia G, et al. Increased activation of p38 MAPK in COPD. Eur Respir J. 2008;31(1):62–69. doi:10.1183/09031936.0003670717959643
   PubMed Web of Science ®Google Scholar
• Patel NR, Cunoosamy DM, Fagerås M, et al. The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial. Int J Chron Obstruct Pulmon Dis. 2018;13:1009–1019. doi:10.2147/COPD.S15057629628759
   PubMed Web of Science ®Google Scholar
• Gaffey K, Reynolds S, Plumb J, Kaur M, Singh D. Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs. Eur Respir J. 2013;42(1):28–41. doi:10.1183/09031936.0017071123060629
   PubMed Web of Science ®Google Scholar
• MacNee W, Allan RJ, Jones I, De Salvo MC, Tan LF. Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial. Thorax. 2013;68(8):738–745. doi:10.1136/thoraxjnl-2012-20274423539534
   PubMed Web of Science ®Google Scholar
• Watz H, Barnacle H, Hartley BF, Chan R. Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2(1):63–72. doi:10.1016/S2213-2600(13)70200-524461903
   PubMed Web of Science ®Google Scholar
• O’Donnell RA, Richter A, Ward J, et al. Expression of ErbB receptors and mucins in the airways of long term current smokers. Thorax. 2004;59(12):1032. doi:10.1136/thx.2004.02804315563701
   PubMed Web of Science ®Google Scholar
• Hussain SS, George S, Singh S, et al. A small molecule BH3-mimetic suppresses cigarette smoke-induced mucous expression in airway epithelial cells. Sci Rep. 2018;8(1):13796. doi:10.1038/s41598-018-32114-w30218002
   PubMed Web of Science ®Google Scholar
• Ngkelo A, Hoffmann RF, Durham AL, et al. Glycogen synthase kinase-3β modulation of glucocorticoid responsiveness in COPD. Am J Physiol Lung Cell Mol Physiol. 2015;309(10):L1112–L1123. doi:10.1152/ajplung.00077.201526320152
   PubMed Web of Science ®Google Scholar
• Liu K, Gualano RC, Hibbs ML, Anderson GP, Bozinovski S. Epidermal growth factor receptor signaling to Erk1/2 and STATs control the intensity of the epithelial inflammatory responses to rhinovirus infection. J Biol Chem. 2008;283(15):9977–9985. doi:10.1074/jbc.M71025720018276593
   PubMed Web of Science ®Google Scholar
• Dry JR, Pavey S, Pratilas CA, et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res. 2010;70(6):2264–2273. doi:10.1158/0008-5472.CAN-09-157720215513
   PubMed Web of Science ®Google Scholar
• Qiagen. Available from: https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/ Accessed 1014, 2019.
   Google Scholar
• Studio P. Available from: https://www.elsevier.com/solutions/pathway-studio-biological-research Accessed 1014, 2019
   Google Scholar
• Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J. 2008;31(4):869–873. doi:10.1183/09031936.0011170718216052
   PubMed Web of Science ®Google Scholar
• Singh D, Fox SM, Tal-Singer R, et al. Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers. Thorax. 2011;66(6):489–495. doi:10.1136/thx.2010.15376721441172
   PubMed Web of Science ®Google Scholar
• Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249–264. doi:10.1093/biostatistics/4.2.24912925520
   PubMed Web of Science ®Google Scholar
• Dai M, Wang P, Boyd AD, et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 2005;33(20):e175–e175. doi:10.1093/nar/gni17916284200
   PubMed Web of Science ®Google Scholar
• Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics. 2013;14:7. doi:10.1186/1471-2105-14-723323831
   PubMed Web of Science ®Google Scholar
• Barrett SD, Bridges AJ, Dudley DT, et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett. 2008;18(24):6501–6504. doi:10.1016/j.bmcl.2008.10.05418952427
   PubMed Web of Science ®Google Scholar
• Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645–2653. doi:10.1056/NEJMoa03215815215480
   PubMed Web of Science ®Google Scholar
• Stefano AD, Capelli A, Lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med. 1998;158(4):1277–1285. doi:10.1164/ajrccm.158.4.98020789769292
   PubMed Web of Science ®Google Scholar
• Kaku Y, Imaoka H, Morimatsu Y, et al. Overexpression of CD163, CD204 and CD206 on alveolar macrophages in the lungs of patients with severe chronic obstructive pulmonary disease. PLoS One. 2014;9(1):e87400. doi:10.1371/journal.pone.008740024498098
   PubMed Web of Science ®Google Scholar
• Caunt CJ, Sale MJ, Smith PD, Cook SJ. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer. 2015;15:577. doi:10.1038/nrc400026399658
   PubMed Web of Science ®Google Scholar
• Liu X, Huang Y, Yang D, et al. Overexpression of TRIM24 is associated with the onset and progress of human hepatocellular carcinoma. PLoS One. 2014;9(1):e85462. doi:10.1371/journal.pone.008546224409330
   PubMed Web of Science ®Google Scholar
• Liu W, Liang Q, Balzar S, Wenzel S, Gorska M, Alam R. Cell-specific activation profile of extracellular signal-regulated kinase 1/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic airways. J Allergy Clin Immunol. 2008;121(4):893–902.e892. doi:10.1016/j.jaci.2008.02.00418395552
   PubMed Web of Science ®Google Scholar
• Duan W, Chan JHP, Wong CH, Leung BP, Wong WSF. Anti-inflammatory effects of mitogen-activated protein kinase kinase inhibitor U0126 in an asthma mouse model. J Immunol. 2004;172(11):7053–7059. doi:10.4049/jimmunol.172.11.705315153527
   PubMed Web of Science ®Google Scholar
• Cohen TS, Gray Lawrence G, Khasgiwala A, Margulies SS. MAPk activation modulates permeability of isolated rat alveolar epithelial cell monolayers following cyclic stretch. PLoS One. 2010;5(4):e10385. doi:10.1371/journal.pone.001038520442784
   PubMed Web of Science ®Google Scholar
• Cohen TS, Gray Lawrence G, Margulies SS. Cultured alveolar epithelial cells from septic rats mimic in vivo septic lung. PLoS One. 2010;5(6):e11322. doi:10.1371/journal.pone.001132220593014
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Alveolar macrophages as orchestrators of COPD. J Chron Obstruct Pulmon Dis. 2004;1(1):59–70. doi:10.1081/COPD-120028701
   Google Scholar
• Finkelstein R, Fraser RS, Ghezzo H, Cosio MG. Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med. 1995;152(5):1666–1672. doi:10.1164/ajrccm.152.5.75823127582312
   PubMed Web of Science ®Google Scholar
• Shi-Lin D, Yuan X, Zhan S, Luo-Jia T, Chao-Yang T. Trametinib, a novel MEK kinase inhibitor, suppresses lipopolysaccharide-induced tumor necrosis factor (TNF)-α production and endotoxin shock. Biochem Biophys Res Commun. 2015;458(3):667–673. doi:10.1016/j.bbrc.2015.01.16025684183
   PubMed Web of Science ®Google Scholar
• Li P, Wu Y, Li M, Qiu X, Bai X, Zhao X. AS-703026 inhibits LPS-induced TNFα production through MEK/ERK dependent and independent mechanisms. PLoS One. 2015;10(9):e0137107. doi:10.1371/journal.pone.013710726381508
   PubMed Web of Science ®Google Scholar
• Monick MM, Powers LS, Barrett CW, et al. Constitutive ERK MAP kinase activity regulates macrophage ATP production and mitochondrial integrity. J Immunol. 2008;180(11):7485–7496. doi:10.4049/jimmunol.180.11.748518490749
   PubMed Web of Science ®Google Scholar
• Chanteux H, Guisset AC, Pilette C, Sibille Y. LPS induces IL-10 production by human alveolar macrophages via MAPKinases- and Sp1-dependent mechanisms. Respir Res. 2007;8(1):71. doi:10.1186/1465-9921-8-7117916230
   PubMed Web of Science ®Google Scholar
• Xu Y, Ito T, Fushimi S, et al. Spred-2 deficiency exacerbates lipopolysaccharide-induced acute lung inflammation in mice. PLoS One. 2014;9(10):e108914. doi:10.1371/journal.pone.010891425275324
   PubMed Web of Science ®Google Scholar
• Bode JG, Ehlting C, Häussinger D. The macrophage response towards LPS and its control through the p38MAPK–STAT3 axis. Cell Signal. 2012;24(6):1185–1194. doi:10.1016/j.cellsig.2012.01.01822330073
   PubMed Web of Science ®Google Scholar
• Hoogerwerf JJ, AFd V, Cvt V, et al. Priming of alveolar macrophages upon instillation of lipopolysaccharide in the human lung. Am J Respir Cell Mol Biol. 2010;42(3):349–356. doi:10.1165/rcmb.2008-0362OC19448156
   PubMed Web of Science ®Google Scholar
• Higham A, Booth G, Lea S, Southworth T, Plumb J, Singh DJRR. The effects of corticosteroids on COPD lung macrophages: a pooled analysis. Respir Res. 2015;16(1):98. doi:10.1186/s12931-015-0260-026289362
   PubMed Web of Science ®Google Scholar
• Armstrong J, Harbron C, Lea S, et al. Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2011;338(3):732–740. doi:10.1124/jpet.111.18073721610141
   PubMed Web of Science ®Google Scholar
• Ratcliffe MJ, Dougall IG. Comparison of the anti-inflammatory effects of cilomilast, budesonide and a p38 mitogen activated protein kinase inhibitor in COPD lung tissue macrophages. BMC Pharmacol Toxicol. 2012;13:15. doi:10.1186/2050-6511-13-1523148608
   PubMed Web of Science ®Google Scholar
• Shimo T, Matsumura S, Ibaragi S, et al. Specific inhibitor of MEK-mediated cross-talk between ERK and p38 MAPK during differentiation of human osteosarcoma cells. J Cell Commun Signal. 2007;1(2):103–111. doi:10.1007/s12079-007-0010-218481201
   PubMed Web of Science ®Google Scholar
• New L, Li Y, Ge B, et al. SB203580 promotes EGF-stimulated early morphological differentiation in PC12 cell through activating ERK pathway. J Cell Biochem. 2001;83(4):585–596.11746502
   PubMed Web of Science ®Google Scholar
• Bowers EC, McCullough SD, Morgan DS, Dailey LA, Diaz-Sanchez D. ERK1/2 and p38 regulate inter-individual variability in ozone-mediated IL-8 gene expression in primary human bronchial epithelial cells. Sci Rep. 2018;8:9398. doi:10.1038/s41598-018-27662-029925859
   PubMed Web of Science ®Google Scholar
• Sharma G-D, He J, Bazan HEP. p38 and ERK1/2 Coordinate Cellular migration and proliferation in epithelial wound healing: evidence of cross-talk activation between map kinase cascades. J Biol Chem. 2003;278(24):21989–21997. doi:10.1074/jbc.M30265020012663671
   PubMed Web of Science ®Google Scholar
• Carter AB, Monick MM, Hunninghake GW. Both Erk and p38 Kinases are necessary for cytokine gene transcription. Am J Respir Cell Mol Biol. 1999;20(4):751–758. doi:10.1165/ajrcmb.20.4.342010101008
   PubMed Web of Science ®Google Scholar
• Jubrail J, Kurian N, Niedergang F. Macrophage phagocytosis cracking the defect code in COPD. Biomed J. 2017;40(6):305–312. doi:10.1016/j.bj.2017.09.00429433833
   PubMed Web of Science ®Google Scholar
• Singh R, Garcha D, Patel A, Mackay A, Donaldson G, Wedzicha J. The impact of bacterial colonisation on airway inflammation in stable COPD. Eur Respir J. 2012;40(Suppl 56). doi:10.1183/09031936.00213711
   Web of Science ®Google Scholar
• Singh R, Mackay A, Brill S, et al. Effect of lower airway bacterial colonisation on time to acute exacerbation in patients with COPD. Eur Respir J. 2015;46(suppl 59):PA661.
   Google Scholar
• Smith JA, Mayeux PR, Schnellmann RG. Delayed MEK/ERK inhibition by trametinib attenuates systemic inflammatory responses and multi-organ injury in murine sepsis. Crit Care Med. 2016;44(8):e711–e720. doi:10.1097/CCM.000000000000167227031380
   PubMed Web of Science ®Google Scholar
• Long ME, Gong K-Q, Eddy WE, Liles WC, Manicone AM. Pharmacologic inhibition of MEK1/2 reduces lung inflammation without impairing bacterial clearance in experimental pseudomonas aeruginosa pneumonia. Pneumonia. 2017;9:13. doi:10.1186/s41479-017-0037-y28879065
   PubMed Web of Science ®Google Scholar
• Long ME, Eddy WE, Gong K-Q, et al. MEK1/2 inhibition promotes macrophage reparative properties. J Immunol. 2017;198(2):862–872. doi:10.4049/jimmunol.160105928003382
   PubMed Web of Science ®Google Scholar
• Droebner K, Pleschka S, Ludwig S, Planz O. Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo. Antiviral Res. 2011;92(2):195–203. doi:10.1016/j.antiviral.2011.08.00221854809
   PubMed Web of Science ®Google Scholar
• Haasbach E, Müller C, Ehrhardt C, et al. The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo. Antiviral Res. 2017;142:178–184. doi:10.1016/j.antiviral.2017.03.02428377100
   PubMed Web of Science ®Google Scholar
• Baturcam E, Vollmer S, Schlüter H, et al. MEK inhibition drives anti-viral defence in RV but not RSV challenged human airway epithelial cells through AKT/p70S6K/4E-BP1 signalling. Cell Commun Signaling. 2019;17(1):78. doi:10.1186/s12964-019-0378-7
   Web of Science ®Google Scholar
• Pleschka S, Wolff T, Ehrhardt C, et al. Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat Cell Biol. 2001;3(3):301–305. doi:10.1038/3506009811231581
   PubMed Web of Science ®Google Scholar